Who Paid My Doc
Michael Wildes
Cornea and External Diseases Specialist Aurora, CO Medical Doctor
NPI 1396163929 CMS profile 1399203
1675 Aurora Ct, Aurora, CO 80045
General payments
$1,074
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Michael Wildes of Aurora, CO is reported in the CMS Open Payments database as having received $1,074 across 26 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 35th percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $36 | 1 | |
| 2023 | General | $115 | 1 | |
| 2022 | General | $361 | 3 | |
| 2021 | General | $274 | 10 | |
| 2020 | General | $108 | 6 | |
| 2019 | General | $179 | 5 |
Beside peers
- Michael Wildes
- Cornea and External Diseases Specialist median
- Middle half of Cornea and External Diseases Specialist
- National median
In program year 2025, general payments to Michael Wildes were reported at $0. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.
Show as a table
| Year | Michael Wildes | Cornea and External Diseases Specialist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $179 | $276 | $111–$734 | $163 |
| 2020 | $108 | $146 | $48–$330 | $114 |
| 2021 | $274 | $254 | $116–$566 | $132 |
| 2022 | $361 | $251 | $106–$729 | $149 |
| 2023 | $115 | $344 | $149–$759 | $160 |
| 2024 | $36 | $366 | $170–$927 | $164 |
| 2025 | $0 | $477 | $193–$1,174 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
1,392
Drug cost
$160,673
Branded share of claims
31.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Restasis Cyclosporine | Brand | 63 | $71,138 | |
| Xiidra Lifitegrast | Brand | 22 | $25,054 | |
| Prednisolone Acetate | Generic | 429 | $15,750 | |
| Restasis Multidose Cyclosporine | Brand | 15 | $9,812 | |
| Ketorolac Tromethamine | Generic | 247 | $9,771 | |
| Fluorometholone | Generic | 124 | $9,540 | |
| Cyclosporine | Generic | 14 | $7,216 | |
| Moxifloxacin Moxifloxacin Hcl | Brand | 124 | $3,685 | |
| Valacyclovir Valacyclovir Hcl | Brand | 46 | $3,633 | |
| Erythromycin Erythromycin Base | Brand | 107 | $1,356 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 42 billing codesPaid by Medicare
$150,477
Medicare patients
427
Services billed
1,117
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 68% | |
| Arthritis | 49% | |
| Ischemic heart disease | 29% | |
| Diabetes | 28% | |
| Chronic kidney disease | 26% | |
| Depression | 25% | |
| Cancer | 18% | |
| Osteoporosis | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
26 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cornea and External Diseases Specialist in Colorado
Michael Taravella
Cornea and External Diseases Specialist · Aurora, CO
Karen Christopher
Cornea and External Diseases Specialist · Aurora, CO
Aimee Verner
Cornea and External Diseases Specialist · Longmont, CO
Christopher Gelston
Cornea and External Diseases Specialist · Aurora, CO
Christopher Hampton
Cornea and External Diseases Specialist · Wheat Ridge, CO
Ronald Wise
Cornea and External Diseases Specialist · Denver, CO
Related records
Cornea and External Diseases Specialist in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Cornea and External Diseases Specialist
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.